T1	Participants 68 86	autistic children.
T2	Participants 284 310	autistic children (n = 41)
T3	Participants 348 444	parallel groups design with fixed dose was used, with random assignment to naltrexone or placebo
T4	Participants 584 595	17 children
T5	Participants 968 1030	children receiving naltrexone in the highest weight percentile
